Business Wire

conova deploys ADVA OLS solution for highly secure DCI connectivity

Share

ADVA (FSE: ADV) today announced that conova communications is using its technology for secure, high-capacity transport between data centers. conova, one of Austria’s leading IT service providers, has deployed the ADVA FSP 3000 open line system (OLS) with ConnectGuard™ Optical encryption in response to booming demand from business customers for reliable and protected cloud services. The fully redundant infrastructure supports 100Gbit/s Carrier Ethernet as well as 32Gbit/s Gen 6 Fibre Channel, a key requirement for the most advanced enterprise storage services. Featuring ADVA ALM fiber assurance technology, the new DCI network also enables rapid repair times and improves performance. The solution was designed and implemented by ADVA’s Elite partner dacoso, a German IT service provider focusing on connectivity, cyber defense and virtual networking.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005076/en/

ADVA's technology takes conova's DCI network to new heights (Photo: Business Wire)

ADVA's technology takes conova's DCI network to new heights (Photo: Business Wire)

“In recent years, we’ve grown rapidly as our customers’ businesses have expanded. ADVA’s technology enables us to meet new levels of demand for high-security, high-availability cloud and storage services in a way that also supports further growth in the future. With the ability to transport the most advanced low-latency 32Gbit/s Fibre Channel services, our new network also empowers us to realize the full value of our state-of-the-art data centers,” said Stefan Kaltenbrunner, CSO, conova. “Our new fully redundant network is key to our mission of delivering the optimal IT infrastructure for every business. It helps us provide our customers with fast access to their mission-critical data around the clock as well as the peace of mind that comes from knowing that it’s safe and secure.”

conova’s new network is built on the ADVA FSP 3000 OLS, a high-performance packet-optical solution with low-power consumption and an extremely compact design. The infrastructure is protected by ConnectGuard™ Optical for network encryption at the lowest network layer. This is not only the most robust security method available, but it also maximizes throughput and ensures the lowest possible latency. The network is assured by the ADVA ALM fiber monitoring solution, which provides real-time information on fiber integrity for fast failure detection and short repair cycles. As the first platform on the market to achieve mainframe qualification for Gen 6 Fibre Channel transport, the ADVA FSP 3000 enables conova to make the leap to 32Gbit/s Fibre Channel and maximize the performance of flash-enhanced data storage in its facilities.

“When it comes to data center interconnect technology that offers agility, security and speed, our portfolio and our team are second to none. We’ve provided conova with a network optimized for the fastest, most reliable SAN connectivity. Now its team is free to tackle soaring data demand using flash storage and other latest-generation technologies,” commented Andreas Jelinek, senior director, sales, Eastern Europe, Russia and CIS, ADVA. “Today’s enterprise customers need their data to be constantly available but also expect it to be fully protected. With our simple and effective technology, conova’s customers can be assured that all data and control traffic is safe. What’s more, as our ConnectGuard™ Optical encryption technology adds just 100ns of latency, total security comes at virtually no cost to performance.”

“Together with ADVA, we’ve delivered the ideal DCI network for conova’s specific needs. It’s a future-proof solution that ensures excellent performance as well as robust protection of data integrity,” said Christian Cehovin, country manager, Austria, dacoso. “We’ve worked very closely with ADVA on this project to ensure there could be no room for error. Together we’ve built up a formidable reputation for designing and installing solutions that provide low-latency, high-capacity transport for business continuity and disaster recovery. conova’s solution is the product of ADVA’s world-class technology, the energy and passion of our team and a wealth of combined expertise. And, with our ongoing maintenance and support, it’s sure to provide value for conova’s customers for many years to come.”

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex and Republic of Ireland Expand Long-Term Cystic Fibrosis Medicines Reimbursement Agreement to Include Triple Combination Therapy for All Eligible Patients Ages 12 and Over Once Licensed13.12.2019 18:55:00 CETPress release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that, following recent collaborative discussions, it has negotiated an agreement with the Health Service Executive (HSE) in the Republic of Ireland to expand the existing long-term cystic fibrosis (CF) reimbursement agreement to include the triple combination regimen (elexacaftor, tezacaftor and ivacaftor), which is under review and pending approval by the European Medicines Agency, for all eligible patients ages 12 and older in line with the potential future licensed indication. This expands the existing agreement which had already included access to current and future Vertex medicines for people in Ireland with CF of any age who: Have one of the specified mutations as included in the KALYDECO® marketing authorization (G551D, G551S, S549R, G1244E, S1251N, G1349D, S1255P, G178R or S549N) or Are homozygous for the F508del mutation or Are heterozygous for the F508del mutation and have a specified mutation (P67L, D579G, D1

CreditLens™ Solution Receives SOC 2 Attestation Report13.12.2019 15:17:00 CETPress release

Moody’s Analytics announced today that the CreditLens software-as-a-service (SaaS) solution has received an attestation report from the American Institute of Certified Public Accountants (AICPA) System and Organization Controls (SOC 2). The SOC 2 report details the security and availability of customer data in the CreditLens SaaS solution, and denotes its adherence to the AICPA’s security and availability controls standards. Built on the latest cloud-based technology, the CreditLens platform helps businesses digitally transform their commercial credit processes to make faster and better-informed decisions. It facilitates process automation and helps clients improve their efficiency, reduce errors, and streamline workflows. A SOC 2 report ensures that a company’s information security measures are in line with the unique parameters of today’s cloud requirements. The report addresses a service organization's controls that relate to operations and compliance, as outlined by the AICPA's Tru

CHMP Grants Positive Opinion for Expanded Use of Darzalex®▼ (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible13.12.2019 11:47:00 CETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended broadening the existing marketing authorisation for Darzalex®▼ (daratumumab) to include the use of daratumumab in combination with bortezomib, thalidomide and dexamethasone (VTd) for the treatment of adult patients with newly diagnosed patients with multiple myeloma who are eligible for autologous stem cell transplant (ASCT). The Positive Opinion is supported by data from Part 1 of the Phase 3 CASSIOPEIA (MMY3006) study, published in The Lancet 3 in June 2019, and presented at the 2019 American Society of Clinical Oncology (ASCO) Meeting. Additional information about this study can be found at www.ClinicalTrials.gov (NCT02541383). “Today’s Opinion takes us a step closer to offering the first daratumumab combination regimen to transplant eligible patients, redefining treatment for those people newl

Janssen Receives Positive CHMP Opinion for Expanded Use of Erleada® (apalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer13.12.2019 11:40:00 CETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending approval for expanding the use of Erleada® (apalutamide) to include the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).2 The CHMP’s Positive Opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the new use of apalutamide. The Positive Opinion is based on data from the Phase 3 TITAN study, which assessed the addition of apalutamide to ADT – the current standard of care in mHSPC – in a broad range of patients with mHSPC, regardless of disease volume, prior treatment with docetaxel or staging at initial diagnosis. The dual primary endpoints of the study were overall survival (OS) and radiographic progression-free survival (rPFS). Ap

German Player Karl Rupprec Wins 2019 Boyaa Poker Tournament Europe13.12.2019 09:24:00 CETPress release

On December 8, the sixth edition of the BPT (Boyaa Poker Tournament) came to an end. King's Resort in the Czech Republic celebrated this BPT Europe that enjoyed 600 cumulative participants from 20 countries. In the end, Karl Rupprec, from Germany, won the Main Event Championship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191213005109/en/ (Photo: Business Wire) Highlights of the BPT Europe 2019 final The BPT Europe 2019 Main Event began on December 8 at 2:00 p.m., Czech Republic time. After 9 hours of Texas Poker, players Ondrej Drozd from the Czech Republic and Karl Rupprec from Germany reached the last heads-up. In the end, Karl Rupprec, who started with half of his opponent's chips, reversed the situation with his two nines, winning the championship. Heads-up Highlights: Karl Rupprec pair 9 and Ondrej Drozd 2, 5. The flop was 2, Q, 9, so Karl Rupprec got three of a kind, and Ondrej Drozd got pair 2. Rupprec pretended

Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Adopted by Italian Designed Architectural Lighting Brand for Motorized Luminaire with Smart Wireless Controls13.12.2019 09:00:00 CETPress release

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED technology, announced that it has achieved smart lighting design with SunLike Series natural spectrum LEDs in cooperation with Casambi Technologies Oy (“Casambi”), a leading developer of wireless lighting control systems based on Bluetooth Low Energy (BLE), and it has been adopted for the Italian designed architectural lighting brand formalighting Ltd. (“formalighting”), a global manufacturer of Italian designed architectural lighting systems and solutions for a new product line which offers motorized luminaire with smart wireless controls. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191213005009/en/ SunLike implemented in motion lamps (Photo: Business Wire) The SunLike COB LED packages have been adopted by formalighting for the new fixtures, Moto-Zero 40 Compasso and Moto-Zero 66 Zoom, in track mounted motorized spotlight range. In this sect